Patent intelligence · US
US 8692051
Methods for testing for caloric restriction (CR) mimetics
Methods for testing for caloric restriction (CR) mimetics
Patent details — US 8692051
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 8, 2014
- Expiration
- Apr 3, 2034
- Applicant
- BioMarker Pharmaceuticals, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K36/87, A61K49/0008
Quick answer
US 8692051 (Methods for testing for caloric restriction (CR) mimetics) is held by BioMarker Pharmaceuticals, Inc.. Status: granted. Granted Apr 8, 2014. Expires Apr 3, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioMarker Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K36/87, A61K49/0008
More from BioMarker Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted -
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 8692051?
US 8692051 (Methods for testing for caloric restriction (CR) mimetics) is held by BioMarker Pharmaceuticals, Inc.. Status: granted. Granted Apr 8, 2014. Expires Apr 3, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8692051?
BioMarker Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 8692051 expire?
Our index shows an expiration date of Apr 3, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.